China Plasma Protease C1-inhibitor Market Size & Outlook
China plasma protease c1-inhibitor market, 2018-2030 (US$M)
Related Markets
China plasma protease c1-inhibitor market highlights
- The China plasma protease c1-inhibitor market generated a revenue of USD 203.0 million in 2023 and is expected to reach USD 371.5 million by 2030.
- The China market is expected to grow at a CAGR of 9% from 2024 to 2030.
- In terms of segment, c1-inhibitors was the largest revenue generating drug class in 2023.
- Selective Bradykinin B2 Receptor Antagonist is the most lucrative drug class segment registering the fastest growth during the forecast period.
Plasma protease c1-inhibitor market data book summary
| Market revenue in 2023 | USD 203.0 million |
| Market revenue in 2030 | USD 371.5 million |
| Growth rate | 9% (CAGR from 2023 to 2030) |
| Largest segment | C1-inhibitors |
| Fastest growing segment | Selective Bradykinin B2 Receptor Antagonist |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist |
| Key market players worldwide | CSL Ltd, Takeda Pharmaceutical Co Ltd, Pharming Group, KalVista Pharmaceuticals Inc, Sanquin, BioCryst Pharmaceuticals Inc, Centogene NV Ordinary Shares |
Other key industry trends
- In terms of revenue, China accounted for 6.1% of the global plasma protease c1-inhibitor market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, India plasma protease c1-inhibitor market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 378.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasma Protease C1-inhibitor Market Scope
Plasma Protease C1-inhibitor Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China plasma protease c1-inhibitor market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasma protease c1-inhibitor market will help companies and investors design strategic landscapes.
C1-inhibitors was the largest segment with a revenue share of 53.15% in 2023. Horizon Databook has segmented the China plasma protease c1-inhibitor market based on c1-inhibitors, kallikrein inhibitor, selective bradykinin b2 receptor antagonist covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to China plasma protease c1-inhibitor market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China plasma protease c1-inhibitor market databook
-
Our clientele includes a mix of plasma protease c1-inhibitor market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China plasma protease c1-inhibitor market , including forecasts for subscribers. This country databook contains high-level insights into China plasma protease c1-inhibitor market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China plasma protease c1-inhibitor market size, by drug class, 2018-2030 (US$M)
China Plasma Protease C1-inhibitor Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
